Navnath Gavande

Dr. Navnath Gavande

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2023 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
JKJeremy M. Kelm
Jeremy M. Kelm
DPDeepti S. Pandey
Deepti S. Pandey
EMEvan Malin
Evan Malin
HKHussein Kansou
Hussein Kansou
SASahil Arora
Sahil Arora
Navnath GavandeNavnath Gavande
Navnath Gavande
Molecularly targeted cancer therapies substantially improve patient outcomes, although the durability of their effectiveness can be limited. Resistance to these therapies is often related to adaptive changes in the target oncoprotein which reduce binding affinity. The arsenal of targeted cancer therapies, moreover, lacks coverage of several notorious oncoproteins with challenging features for inhibitor development. Degraders are a relatively new therapeutic modality which deplete the target protein by hijacking the cellular protein destruction machinery. Degraders offer several advantages for cancer therapy including resiliency to acquired mutations in the target protein, enhanced selectivity, lower dosing requirements, and the potential to abrogate oncogenic transcription factors and scaffolding proteins. Herein, we review the development of proteolysis targeting chimeras (PROTACs) for selected cancer therapy targets and their reported biological activities. The medicinal chemistry of PROTAC design has been a challenging area of active research, but the recent advances in the field will usher in an era of rational degrader design.

29 October 2020 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
Navnath GavandeNavnath Gavande
Navnath Gavande
PVPamela S VanderVere-Carozza
Pamela S VanderVere-Carozza
KPKatherine S Pawelczak
Katherine S Pawelczak
PMPamela Mendoza-Munoz
Pamela Mendoza-Munoz
TVTyler L Vernon
Tyler L Vernon
John J. TurchiJohn J. Turchi
John J. Turchi
DNA-dependent protein kinase (DNA-PK) plays a critical role in the non-homologous end joining (NHEJ) repair pathway and the DNA damage response (DDR). DNA-PK has therefore been pursued for the development of anti-cancer therapeutics in combination with ionizing radiation (IR). We report the discovery of a new class of DNA-PK inhibitors that act via a novel mechanism of action, inhibition of the Ku–DNA interaction. We have developed a series of highly potent and specific Ku–DNA binding inhibitors (Ku-DBi’s) that block the Ku–DNA interaction and inhibit DNA-PK kinase activity. Ku-DBi’s directly interact with the Ku and inhibit in vitro NHEJ, cellular NHEJ, and potentiate the cellular activity of radiomimetic agents and IR. Analysis of Ku-null cells demonstrates that Ku-DBi’s cellular activity is a direct result of Ku inhibition, as Ku-null cells are insensitive to Ku-DBi’s. The utility of Ku-DBi’s was also revealed in a CRISPR gene-editing model where we demonstrate that the efficiency of gene insertion events was increased in cells pre-treated with Ku-DBi’s, consistent with inhibition of NHEJ and activation of homologous recombination to facilitate gene insertion. These data demonstrate the discovery and application of new series of compounds that modulate DNA repair pathways via a unique mechanism of action.

1 February 2021 in Bioorganic Chemistry
Verified
Journal Article
Closed access
GJGaurav Joshi
Gaurav Joshi
MSManisha Sharma
Manisha Sharma
SKSourav Kalra
Sourav Kalra
Navnath GavandeNavnath Gavande
Navnath Gavande
SSSandeep Singh
Sandeep Singh
RKRaj Kumar
Raj Kumar

2 January 2020 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
Navnath GavandeNavnath Gavande
Navnath Gavande
PVPamela S. VanderVere-Carozza
Pamela S. VanderVere-Carozza
KPKatherine Pawelczak
Katherine Pawelczak
TVTyler L. Vernon
Tyler L. Vernon
MJMatthew R. Jordan
Matthew R. Jordan
John J. TurchiJohn J. Turchi
John J. Turchi

7 February 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
MBMohamad Bakkar
Mohamad Bakkar
SKSara Khalil
Sara Khalil
KBKomal Bhayekar
Komal Bhayekar
Narvadeshwar KushwahaNarvadeshwar Kushwaha
Narvadeshwar Kushwaha
ASAmirreza Samarbakhsh
Amirreza Samarbakhsh
Navnath GavandeNavnath Gavande
Navnath Gavande
Cancer management has traditionally depended on chemotherapy as the mainstay of treatment; however, recent advancements in targeted therapies and immunotherapies have offered new options. Ubiquitin-specific proteases (USPs) have emerged as promising therapeutic targets in cancer treatment due to their crucial roles in regulating protein homeostasis and various essential cellular processes. This review covers the following: (1) the structural and functional characteristics of USPs, highlighting their involvement in key cancer-related pathways, and (2) the discovery, chemical structures, mechanisms of action, and potential clinical implications of USP inhibitors in cancer therapy. Particular attention is given to the role of USP inhibitors in enhancing cancer immunotherapy, e.g., modulation of the tumor microenvironment, effect on regulatory T cell function, and influence on immune checkpoint pathways. Furthermore, this review summarizes the current progress and challenges of clinical trials involving USP inhibitors as cancer therapy. We also discuss the complexities of achieving target selectivity, the ongoing efforts to develop more specific and potent USP inhibitors, and the potential of USP inhibitors to overcome drug resistance and synergize with existing cancer treatments. We finally provide a perspective on future directions in targeting USPs, including the potential for personalized medicine based on specific gene mutations, underscoring their significant potential for enhancing cancer treatment. By elucidating their mechanisms of action, clinical progress, and potential future applications, we hope that this review could serve as a useful resource for both basic scientists and clinicians in the field of cancer therapeutics.

6 April 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
JKJeremy M. Kelm
Jeremy M. Kelm
ASAmirreza Samarbakhsh
Amirreza Samarbakhsh
APAthira Pillai
Athira Pillai
PVPamela S. VanderVere-Carozza
Pamela S. VanderVere-Carozza
HAHariprasad Aruri
Hariprasad Aruri
Navnath GavandeNavnath Gavande
Navnath Gavande
The vast majority of cancer patients receive DNA-damaging drugs or ionizing radiation (IR) during their course of treatment, yet the efficacy of these therapies is tempered by DNA repair and DNA damage response (DDR) pathways. Aberrations in DNA repair and the DDR are observed in many cancer subtypes and can promotede novocarcinogenesis, genomic instability, and ensuing resistance to current cancer therapy. Additionally, stalled or collapsed DNA replication forks present a unique challenge to the double-strand DNA break (DSB) repair system. Of the various inducible DNA lesions, DSBs are the most lethal and thus desirable in the setting of cancer treatment. In mammalian cells, DSBs are typically repaired by the error prone non-homologous end joining pathway (NHEJ) or the high-fidelity homology directed repair (HDR) pathway. Targeting DSB repair pathways using small molecular inhibitors offers a promising mechanism to synergize DNA-damaging drugs and IR while selective inhibition of the NHEJ pathway can induce synthetic lethality in HDR-deficient cancer subtypes. Selective inhibitors of the NHEJ pathway and alternative DSB-repair pathways may also see future use in precision genome editing to direct repair of resulting DSBs created by the HDR pathway. In this review, we highlight the recent advances in the development of inhibitors of the non-phosphatidylinositol 3-kinase-related kinases (non-PIKKs) members of the NHEJ, HDR and minor backup SSA and alt-NHEJ DSB-repair pathways. The inhibitors described within this review target the non-PIKKs mediators of DSB repair including Ku70/80, Artemis, DNA Ligase IV, XRCC4, MRN complex, RPA, RAD51, RAD52, ERCC1-XPF, helicases, and DNA polymerase θ. While the DDR PIKKs remain intensely pursued as therapeutic targets, small molecule inhibition of non-PIKKs represents an emerging opportunity in drug discovery that offers considerable potential to impact cancer treatment.